Previous Close | 31.70 |
Open | 32.43 |
Bid | 32.27 x 800 |
Ask | 33.52 x 800 |
Day's Range | 31.93 - 33.03 |
52 Week Range | 19.35 - 35.92 |
Volume | |
Avg. Volume | 343,658 |
Market Cap | 1.925B |
Beta (5Y Monthly) | 0.60 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.21 |
Earnings Date | Feb 21, 2023 - Feb 27, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 48.25 |
Shares of Xencor (NASDAQ: XNCR) rose 12.6% this week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence. The stock closed at $28.83 on Friday and then rose as high as $33.06 on Thursday. Xencor stock was up as high as 14.7% for the week before falling a bit later in the day Thursday.
MONROVIA, Calif., January 09, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.
Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced an expansion of their collaboration to research, develop and commercialize novel XmAb® bispecific and multi-specific antibodies directed agai